New doubts raised on anemia drugs

Anemia drugs just can't get a break. Now, the FDA is questioning whether the drugs--Amgen's Epogen and Aranesp and J&J's Procrit--actually improve kidney patients' quality of life.

In documents posted in advance of tomorrow's FDA advisory committee meeting, the agency said the data contained "important deficiencies." The committee is scheduled to discuss proper dosing of the drugs, which may increase cardiovascular and cancer risks at high doses. After questions arose about these risks, Medicare changed its reimbursement for the drugs to limit dosing--and it's watching the FDA now to see whether further changes are needed.

- read the Wall Street Journal report (sub. req.)

ALSO: Amgen's decision to cut its workforce maybe spark biotech start-ups. Report

Related Articles:
New rules limit use of anemia drugs. Report
New Medicare cap on anemia drugs could hammer Amgen. Report
FDA panel votes for restrictions on anemia drugs. Report
Amgen stock slips as anemia drug concerns rise. Report
Major challenges loom for Amgen. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.